Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. EQT and Investor make an offer for Gambro
Mandate

EQT and Investor make an offer for Gambro

July 20, 2006

Indap AB, which Investor AB and EQT jointly own indirectly, has announced a cash offer to the shareholders of Gambro AB to transfer shares in Gambro to Indap. The shares in Gambro are registered on the A-list of the Stockholm Stock Exchange. The offer is for 111 Swedish kronor per share of series A and series B shares in Gambro.

Vinge acted as advisor to the bidders. Representatives from Vinge included Hans Wibom, Christoffer Saidac, Göran Nyström, Fredrik von Baumgarten, Fabian Ekeblad, Johan Karlsson, Mattias Schömer, Tuula-Anneli Tallavaara, Niclas Bergström, Ceclia Rudels, Penilla Olsson and Peter Forsberg.

Related

Vinge advises Egetis Therapeutics in connection with ANI Pharmaceuticals’ public cash offer

 On 5 November 2026, ANI Pharmaceuticals, Inc., a U.S. biopharmaceutical company listed on The Nasdaq Global Market, announced a recommended public cash offer to the shareholders of Egetis Therapeutics AB (publ) and to the holder of Egetis’ convertible loan and warrants to tender all shares, the convertible loan and the warrants in Egetis to ANI. The total value of the offer amounts to approximately SEK 5,304 million.
November 10, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

 Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 90 million before transaction costs, with an over-allotment issue of approximately SEK 72 million.
November 09, 2026

Vinge advises SenzaGen on its acquisition of Alcyomics

 SenzaGen AB (publ) has acquired Alcyomics Ltd. The transaction is being financed through a combination of existing cash and a directed issue of convertible bonds.
November 09, 2026